RYSTIGGO® For Adult Patients With Generalized Myasthenia Gravis

Meta Data Analysis

Description	RYSTIGGO® (rozanolixizumab-noli), the first FDA-approved targeted treatment for both anti-AChR Ab+ and anti-MuSK Ab+ adults with gMG.
h1 tags	POWERFUL EFFICACY IN ACTION1 For US Healthcare Professionals Only
h2 tags	First FDA-approved targeted treatment Minimal Symptom Expression (MSE) was achieved Flexible dosing with individualized treatment breaks between cycles Watch the RYSTIGGO Mechanism of Action Video Start Your Patients on RYSTIGGO Access Coding and Billing Support Materials Let's stay connected You are now leaving RystiggoHCP.com
Site Speed	0.22744798660278

Alexa Rank:	0
Site's Traffic

Host	Type	Class	TTL	Target
rystiggohcp.com	HINFO	IN	300